CA3012404A1 - Means and methods for staging, typing and treating a cancerous disease - Google Patents
Means and methods for staging, typing and treating a cancerous disease Download PDFInfo
- Publication number
- CA3012404A1 CA3012404A1 CA3012404A CA3012404A CA3012404A1 CA 3012404 A1 CA3012404 A1 CA 3012404A1 CA 3012404 A CA3012404 A CA 3012404A CA 3012404 A CA3012404 A CA 3012404A CA 3012404 A1 CA3012404 A1 CA 3012404A1
- Authority
- CA
- Canada
- Prior art keywords
- dcc
- cells
- somatic
- cancer
- dccs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16152883.1A EP3199641B1 (en) | 2016-01-27 | 2016-01-27 | Means and methods for staging, typing and treating a cancerous disease |
| EP16152883.1 | 2016-01-27 | ||
| PCT/EP2017/051789 WO2017129753A1 (en) | 2016-01-27 | 2017-01-27 | Means and methods for staging, typing and treating a cancerous disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3012404A1 true CA3012404A1 (en) | 2017-08-03 |
Family
ID=55310656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3012404A Pending CA3012404A1 (en) | 2016-01-27 | 2017-01-27 | Means and methods for staging, typing and treating a cancerous disease |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11702701B2 (https=) |
| EP (2) | EP3199641B1 (https=) |
| JP (1) | JP2019508032A (https=) |
| KR (1) | KR20180102674A (https=) |
| CN (1) | CN108770360B (https=) |
| AU (1) | AU2017211976B2 (https=) |
| CA (1) | CA3012404A1 (https=) |
| ES (1) | ES2905208T3 (https=) |
| SG (1) | SG11201805990XA (https=) |
| WO (1) | WO2017129753A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2928773T3 (es) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1109938T3 (da) | 1998-09-18 | 2002-05-27 | Micromet Ag | DNA-amplificering af en enkelt celle |
| AU2002216009A1 (en) * | 2000-11-03 | 2002-05-15 | Michael Giesing | Clinical and functional validation of targets from disseminated cancer cells |
| ITRM20110149A1 (it) * | 2011-03-25 | 2012-09-26 | Massimo Zollo | Biomarcatore per la rilevazione di cellule tumorali circolanti e relativi metodi e kit di rilevazione. |
| US20140227692A1 (en) * | 2011-07-08 | 2014-08-14 | Deborah W. Neklason | Methods of detecting hereditary cancer predisposition |
| EP2788768A1 (en) * | 2011-12-10 | 2014-10-15 | Abbott Molecular Inc. | Materials and methods for diagnosis of malignant melanoma and prognosis of metastasis of malignant melanoma |
| WO2015023553A2 (en) * | 2013-08-13 | 2015-02-19 | Bionumerik Pharmaceuticals, Inc. | Contemporaneous, heterogeneously-oriented, multi-targeted therapeutic modification and/or modulation of disease by administration of sulfur- containing, amino acid-specific small molecules |
| ES2730962T3 (es) | 2014-02-05 | 2019-11-13 | Fraunhofer Ges Forschung | Secuenciación libre de errores de ADN |
-
2016
- 2016-01-27 EP EP16152883.1A patent/EP3199641B1/en active Active
- 2016-01-27 ES ES16152883T patent/ES2905208T3/es active Active
-
2017
- 2017-01-27 KR KR1020187024606A patent/KR20180102674A/ko active Pending
- 2017-01-27 AU AU2017211976A patent/AU2017211976B2/en active Active
- 2017-01-27 CN CN201780008861.6A patent/CN108770360B/zh active Active
- 2017-01-27 SG SG11201805990XA patent/SG11201805990XA/en unknown
- 2017-01-27 EP EP17706412.8A patent/EP3408411A1/en not_active Withdrawn
- 2017-01-27 US US16/073,271 patent/US11702701B2/en active Active
- 2017-01-27 CA CA3012404A patent/CA3012404A1/en active Pending
- 2017-01-27 JP JP2018539138A patent/JP2019508032A/ja active Pending
- 2017-01-27 WO PCT/EP2017/051789 patent/WO2017129753A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN108770360A (zh) | 2018-11-06 |
| EP3408411A1 (en) | 2018-12-05 |
| WO2017129753A8 (en) | 2017-10-19 |
| ES2905208T3 (es) | 2022-04-07 |
| EP3199641B1 (en) | 2021-09-29 |
| KR20180102674A (ko) | 2018-09-17 |
| US20190062845A1 (en) | 2019-02-28 |
| JP2019508032A (ja) | 2019-03-28 |
| US11702701B2 (en) | 2023-07-18 |
| CN108770360B (zh) | 2022-06-14 |
| EP3199641A1 (en) | 2017-08-02 |
| SG11201805990XA (en) | 2018-08-30 |
| AU2017211976B2 (en) | 2022-09-22 |
| AU2017211976A1 (en) | 2018-08-02 |
| WO2017129753A1 (en) | 2017-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Radke et al. | The genomic and transcriptional landscape of primary central nervous system lymphoma | |
| Guo et al. | DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and CTCs | |
| Shao et al. | Silencing EGFR-upregulated expression of CD55 and CD59 activates the complement system and sensitizes lung cancer to checkpoint blockade | |
| Lenos et al. | Stem cell functionality is microenvironmentally defined during tumour expansion and therapy response in colon cancer | |
| US20220010385A1 (en) | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors | |
| Perrone et al. | PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients | |
| Ren et al. | Gene expression predicts dormant metastatic breast cancer cell phenotype | |
| Hodgkinson et al. | Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer | |
| Rahrmann et al. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis | |
| Lorenzo-Martín et al. | VAV2 signaling promotes regenerative proliferation in both cutaneous and head and neck squamous cell carcinoma | |
| Wang et al. | Multi-omics analyses reveal biological and clinical insights in recurrent stage I non-small cell lung cancer | |
| US20070220621A1 (en) | Genetic characterization and prognostic significance of cancer stem cells in cancer | |
| Vincenzo et al. | Application of molecular biology of differentiated thyroid cancer for clinical prognostication | |
| Guijarro et al. | Dual Pten/Tp53 suppression promotes sarcoma progression by activating Notch signaling | |
| Mellai et al. | Promoter hypermethylation of the EMP3 gene in a series of 229 human gliomas | |
| Meng et al. | Histone methyltransferase ASH1L primes metastases and metabolic reprogramming of macrophages in the bone niche | |
| Uen et al. | Anchorage independency promoted tumor malignancy of melanoma cells under reattachment through elevated interleukin-8 and CXC chemokine receptor 1 expression | |
| Park et al. | High p16INK4A expression in glioblastoma is associated with senescence phenotype and better prognosis | |
| Lee et al. | Prognostic implication of MET overexpression in myxofibrosarcomas: an integrative array comparative genomic hybridization, real-time quantitative PCR, immunoblotting, and immunohistochemical analysis | |
| US11702701B2 (en) | Means and methods for staging, typing and treating a cancerous disease | |
| Lorenzi et al. | ATRX mutations mediate an immunogenic phenotype and macrophage infiltration in neuroblastoma | |
| Powers et al. | The molecular pathology of sarcomas | |
| CN110684843B (zh) | 罹癌个体样本中生物标记的用途 | |
| Cramer et al. | Forward genetic screening in engineered colorectal cancer organoids identifies novel regulators of metastasis | |
| Zaurito | An extensive cellular and molecular chart of genetic models elucidating the onset and progression of colorectal cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220127 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240807 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241220 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241220 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241220 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241227 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250329 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250329 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251120 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251121 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251210 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251210 |